Advances in MASH: Data from a Phase 3 Study

Description

Join us as we discuss the importance of early identification of MASH (metabolic dysfunction-associated steatohepatitis), including how to accurately identify and select patients who are at risk for clinically significant fibrosis. We will also discuss clinical trial data for patients with MASH and stage 2 or 3 fibrosis.

Industry Supporter: Novo Nordisk, Inc.